Skip to main content
. 2016 Mar 21;34(20):2359–2365. doi: 10.1200/JCO.2015.63.1960

Table A4.

Clinical Characteristics by RS Among Patients With ER-Positive/HER2-Negative De Novo Stage IV Breast Cancer

RS Risk Group, No. (%)
Low Risk
(RS < 18) Intermediate Risk
(RS 18-30) High Risk
(RS ≥ 31) P
No. of patients 22 26 21
Median age, years (range) 58 (38-73) 52 (26-79) 50 (21-77) .246
Median tumor size, cm (range) 2.6 (0.8-9) 3.1 (0.7-15) 3.5 (1-9) .352
ECOG status .651
 0 9 (41) 16 (62) 11 (52)
 > 0 13 (59) 10 (38) 10 (48)
Cohort .001
 A 20 (91) 19 (73) 21 (100)
 B 2 (9) 7 (27) 0 (0)
Site of first metastasis .397
 Bone 14 (64) 14 (54) 10 (48)
 Visceral 5 (23) 6 (23) 3 (14)
 Both 2 (9) 4 (15) 7 (33)
 Other* 1 (4) 2 (8) 1 (5)
No. of metastases .580
 1 16 (73) 16 (62) 11 (52)
 > 1 6 (27) 10 (38) 10 (48)
Tumor grade
 I 5 (23) 0 (0) 1 (5) < .001
 II 15 (68) 11 (52) 3 (15)
 III 2 (9) 10 (48) 16 (80)

Abbreviations: ER, estrogen receptor; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; RS, Recurrence Score.

*

Includes mediastinal lymph nodes, endobronchial lymph nodes, skin, and pleura.

Locally reported tumor grade missing for five patients in the intermediate-risk group and one patient in the high-risk group.